DUBLIN--(BUSINESS WIRE)--Sep 7, 2018--The "Hyperphosphatemia - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Hyperphosphatemia development.The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type

Pipeline Products covered across the following Developmental Stages:

ClinicalNon-clinicalInactive: Discontinued and/or Dormant


The report provides a snapshot of the pipeline development for HyperphosphatemiaThe report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for HyperphosphatemiaThe report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical informationProvides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for HyperphosphatemiaThe report also covers the dormant and discontinued pipeline projects related to HyperphosphatemiaCompanies Featured3SBio Inc.Ardelyx Inc. Daiichi Sankyo Company Ltd.Medice Arzneimittel Putter GmbH & Co. KGOPKO Health Inc.PDX Pharmaceuticals LLCShield Therapeutics PLC

Key Topics Covered

1. Report Introduction

2. Hyperphosphatemia Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Hyperphosphatemia

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name: Company Name

Product DescriptionResearch and DevelopmentProduct Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name: Company Name

Product DescriptionResearch and DevelopmentProduct Development Activities

7. Therapeutic Assessment

Assessment by Route of AdministrationAssessment by Stage and Route of AdministrationAssessment by Molecule TypeAssessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name: Company Name

Product DescriptionResearch and DevelopmentProduct Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/8h762c/2018_pipeline?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180907005285/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hematological Drugs ,Endocrine and Metabolic Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/07/2018 10:26 AM/DISC: 09/07/2018 10:25 AM